Education
About Us
Working with TipRanks
Follow Us
Biomea Fusion (BMEA)
NASDAQ:BMEA
BMEA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.53 - $13.43
Previous CloseN/A
Volume309.16K
Average Volume (3M)743.97K
Market Cap
$65.75M
Enterprise Value$91.20M
Total Cash (Recent Filing)-$239.00K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Aug 04, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding37,572,250
10 Day Avg. Volume853,677
30 Day Avg. Volume743,966
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-21.71
Enterprise Value/Ebitda-0.61
Forecast
1Y Price Target
$20.75Price Target Upside1127.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Biomea Fusion News
PremiumCompany Announcements
Biomea Fusion’s Strategic Shift: A Year of Transformation
PremiumCompany Announcements
Biomea Fusion Appoints Interim CEO Amid Leadership Changes---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsBiomea announced positive topline results from the Phase 2 COVALENT-111 clinical trial evaluating icovamenib in patients with T2D.
Efficacy And SafetyIcovamenib exhibited a mean HbA1c reduction of 1.47% and a 53% increase in C-peptide after 14 weeks off-therapy, with no safety concerns.
Synergistic PotentialInitial preclinical data shows icovamenib synergizes with GLP-1 RAs for glucose control, indicating potential benefits in diabetes treatment.
Bears Say
Cash ReservesThe company ended the year with $58.6 million in cash.
Oncology Trials TerminationBiomea is terminating all ongoing oncology trials for the menin inhibitor candidate.
---
Ownership Overview
17.46% Insiders
14.61% Mutual Funds
20.74% Other Institutional Investors
39.52% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BMEA FAQ
What was Biomea Fusion’s price range in the past 12 months?
Biomea Fusion lowest stock price was $1.53 and its highest was $13.43 in the past 12 months.
What is Biomea Fusion’s market cap?
Biomea Fusion’s market cap is $65.75M.
When is Biomea Fusion’s upcoming earnings report date?
Biomea Fusion’s upcoming earnings report date is Aug 04, 2025 which is in 106 days.
How were Biomea Fusion’s earnings last quarter?
Biomea Fusion released its earnings results on Mar 31, 2025. The company reported -$0.81 earnings per share for the quarter, missing the consensus estimate of -$0.612 by -$0.198.
Is Biomea Fusion overvalued?
According to Wall Street analysts Biomea Fusion’s price is currently Undervalued.
Does Biomea Fusion pay dividends?
Biomea Fusion does not currently pay dividends.
What is Biomea Fusion’s EPS estimate?
Biomea Fusion’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biomea Fusion have?
Biomea Fusion has 37,572,250 shares outstanding.
What happened to Biomea Fusion’s price movement after its last earnings report?
Biomea Fusion reported an EPS of -$0.81 in its last earnings report, missing expectations of -$0.612. Following the earnings report the stock price went down -6.573%.
Which hedge fund is a major shareholder of Biomea Fusion?
Currently, no hedge funds are holding shares in BMEA
---
Biomea Fusion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.75 (1127.81% Upside)
$20.75 (1127.81% Upside)
Blogger Sentiment
Bullish
BMEA Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 575.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.5%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.82%
12-Months-Change
Fundamentals
Return on Equity
-125.38%
Trailing 12-Months
Asset Growth
-60.02%
Trailing 12-Months
Company Description
Biomea Fusion
Biomea Fusion, Inc. (BMEA) is a clinical-stage biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers. The company operates within the healthcare sector, specializing in oncology. Biomea's core products revolve around its proprietary drug discovery platform, which aims to address unmet medical needs by targeting specific genetic mutations in cancer cells.
---
BMEA Stock 12 Month Forecast
Average Price Target
$20.75
▲(1127.81% Upside)
Technical Analysis
Unicycive Therapeutics
―
Acumen Pharmaceuticals
―
Invivyd
―
Lexeo Therapeutics, Inc.
―
Best Analysts Covering BMEA
1 Year
1 Year Success Rate
2/12 ratings generated profit
1 Year Average Return
-10.73%
reiterated a buy rating 6 months ago
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -10.73% per trade.
---